Da Vinci 5 Drives Procedure Growth, but Margin and China Risks Keep ISRG a Hold

What happened

Intuitive Surgical's Q1 2026 results showed da Vinci procedures up 16% YoY, driven by the da Vinci 5 platform, which accounted for 54% of placements and boosted utilization by 4%. However, the deep value report notes that the da Vinci 5 rollout is pressuring gross margins, which management guided to 67.5%-68.5% including a 1% tariff headwind. Additionally, China placements remain disrupted by tender delays and domestic competition, slowing OUS procedure growth to 19% from 24% a year ago. With the stock trading at 57.5x P/E, the premium valuation leaves little room for error if procedure growth slips below the 13.5%-15.5% guidance or if margins deteriorate further. The combination of strong execution on procedures and persistent structural risks keeps the rating at WAIT, requiring confirmation that da Vinci 5 economics stabilize and China recovers.

Implication

ISRG's installed base and recurring revenue model provide a long-term moat, but near-term headwinds from da Vinci 5 cost pressures and China disruption warrant patience. Investors should monitor quarterly procedure growth and gross margin trends; a sustained 15%+ procedure growth with margins above 68% could trigger re-rating, while any miss below 13.5% would increase downside risk. The bear case of $430 implies significant downside from current levels, so prudent investors should wait for confirmation of stable economics or a pullback to attractive entry levels.

Thesis delta

The Q1 results confirm strong procedure momentum but do not resolve the key margin and China risks that underpin the WAIT rating. The thesis remains unchanged: near-term upside is capped by valuation unless margins stabilize and China placement cadence recovers. No material shift; the report's trigger points (procedures <13.5% or margins <67%) remain active.